|
The American has an article by Roger Bate assessing current compulsory licensing trends at WHO:
The drug companies have tried voice: they have pointed out the need to make some profit from middle-income markets; they have complained to governments, activists, the media, and anyone that will listen; and they have tried litigation and threats of exit. Perhaps it is time to actually try exit.
The first to take action might be Novartis. According to several sources, the company has shelved plans to build a $500 million factory in Brazil that would manufacture an anti-meningitis vaccine.
posted by Solveig Singleton @ 8:12 AM | International, Patents, Pharma
Link to this Entry |
Printer-Friendly |
Email a Comment | Post a Comment(1)
|